A novel scoring system to analyze combined effect of lifestyle factors on pancreatic cancer risk: a retrospective case-control study

Tianshu Pang1, Guoping Ding1, Zhengrong Wu1, Guixing Jiang1, Yifei Yang2, Xiaofei Zhang3 & Liping Cao1

Although several risk factors for the onset of pancreatic ductal adenocarcinoma (PDAC) have been identified, currently, no scoring system to systemically evaluate the risk of PDAC has been established. In this study, we aimed to use a population of over 1200 patients to build a novel scoring system, and evaluated combined effects of risk factors for PDAC patients. A set of 4904 participants including 1274 PDAC patients and 3630 non-cancer individuals were recruited for the single-center study over 17-year period (1997~2013). Systematic logical analysis were presented for case and control groups, and a risk rating system was constructed to assess combined risk factors. Seven independent risk factors were identified with the increased risk of PDAC, were selected into the risk score. A merged risk assessment model was established, demonstrating significantly increased PDAC risk in following a number of rising scores. Individuals with scores from 1 to more than 4, the responding OR (95% CI) were 3.06 (2.57~3.65), 7.08 (5.63~8.91), 22.4 (14.2~35.4), and 31.4 (12.7~77.5), respectively. The integer-based risk score in the study can be used for risk stratification to accurately evaluate PDAC occurrence at an early stage. This scoring system provides an accurate risk assessment of PDAC risk.

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic malignancy, is a high lethal pancreatic tumor. Pancreatic cancer is the fourth leading cause of cancer death in the United States and the twelfth in the world1-3. At least 250,000 individuals worldwide are suffered PDAC annually, which accounts for around 3% systemic malignant tumors4,5. It is estimated that PDAC would become the primary cause of cancer death in 20504. With regard to China, about 32,100 deaths were attributed to PDAC in 1990, and this number was rapidly increased to 58,200 in 20106. According to statistics, 85% of patients with PDAC were diagnosed at a late stage7. An annual report from 1975 to 2002 indicated that the 5-year survival rate of patients involved with curative resection had reached to 20%, however, only 10~15% of all the PDAC patients had access to radical surgery, and the majority died within one or two years after diagnosis8. The overall 5-year survival rate is about 8%, being improved slightly over the past five years9.

The investigation of the relationship between PDAC and its pathogenesis has been increased since the increasing prevalence of pancreatic malignancy worldwide. Single risk factor assessment studies show that 30%~40% of PDAC cases are attributable to known factors including family history, genetic disorders, environmental exposure, tobacco use, occupation and job exposures, medical conditions and lifestyle factors5. Both demographics and medical characteristics have an effect on the increased risk for PDAC occurrence, such as smoking11,12, heavy amounts of alcohol drinking13-15, diabetes16-18, chronic pancreatitis19,20, and family history of PDAC5,21. However, information on epidemiologic characteristics of multiple risk factors associated with PDAC is very limited22. To evaluate the effect of multiple risk factors on PDAC developing, we scored Chinese participants based on their conformity to risk rating using certain potentially modifiable risk factors. Associations between combined variables multiple risks of PDAC were examined.

1Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3, Qingchun Road, Hangzhou, China. 2Department of General Surgery, First People’s Hospital of Yuhang District, Hangzhou, China. 3Department of Clinical Epidemiology & Biostatistics, Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou, China. Correspondence and requests for materials should be addressed to L.C. (email: caolipingzju@126.com)
Materials and Methods

Study design. This was a retrospective case-control study. Records from patients undergoing PDAC from 1st July 1997 to 30th June 2013 from clinical database of our medical centers in affiliated hospital of Zhejiang University medical college, were evaluated to assess risk factors for PDAC development. Stepwise screening involved 1274 eligible patients (805 males/469 females) (Fig. 1) and 3630 health individuals (1835 males/1795 females) were selected for case group and control group. Since PDAC patients were among 41~93 years old, we excluded those younger than 40 and older than 90 years from control group. The controls were ordinarily residents in the same area, going through annual routine physical examination in the same hospital between 1997~2013. The participants did not have a family history of pancreatic cancer nor history of malignant tumors. Patients underwent surgical procedure, including radical, palliative or exploratory operation were diagnosed by postoperative histopathological examination, and others without surgery were diagnosed by preoperative fine needle aspiration pathology. Both case and control groups were local Chinese residents from Zhejiang, Anhui, Jiangsu and Jiangxi Province.

Data collection. The research protocol was reviewed and approved by the Research Ethics Committee of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University. The Institutional Review Board of the hospital approved the query of a maintained database to identify inpatients with the diagnosis of pancreatic cancer. The local ethics committee of the hospital also approved the study protocol. A dedicated interview was conducted face to face with each patient by trained doctors that equipped with qualification certificate. And physicians of health examination recorded basic medical information of the controls. We got access to medical records of case group from Hospital Record Department. The protocol in this retrospective clinical study was performed in accordance with the principles of Helsinki Declaration.

The information collected includes general situation of age, sex, height, smoking and drinking habits, family history of diseases, medical history of gastritis, chronic pancreatitis (CP), cholelithiasis, cholecystectomy, gallbladder polyps, hypertension, diabetes (DM). The preoperative blood specimen collection was taken following a standardized checklist early next morning before breakfast in hospitalization. The preoperative blood specimen collection includes fasting blood glucose (FBG), albumin/globulin (A/G) ratio, alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), alpha-L-fucosidase (AFU), total cholesterol, triglycerides, high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C). Smokers/drinkers were defined as those who had been continuously or cumulatively smoking/drinking for at least one year in their lifetime, whereas nonsmokers/nondrinkers were defined as those who had not23. The amount of smoking was expressed by pack-years, which is equal to number of cigarettes smoked per day × number of years smoked/20 (1 pack has 20 cigarettes)24. Alcohol consumption was classified as low dose (0~1 drink/day) and high dose (>1 drink/day)25. Family history of PDAC was collected among first-degree relatives, and those with familial cancer syndromes were excluded. TC/HDL-C ratio is calculated with a demarcation point of 526. Among case and control groups, people with gallstones or

---

**Figure 1.** Screening of flow chart for PDAC patients.
considered statistically significant for all statistical analyses. P values were based on two-sided tests and values of P < 0.05 were assigned a value of 0. Individual score was assigned to each participant’s record by summing the score of risk variables. The referent for each independent variable was assigned a value of 0. Related variables were put through forward and backward stepwise regression of likelihood ratio in unconditional logistic regression analysis. To further investigate the influence in combined risk predictors, we performed multivariate logistic regression analysis. Factors with a P value of < 0.05 and with potential clinical relevance were analyzed into a multivariate logistic regression analysis. Wald χ2/Z values in the model were used to estimate odds ratio (OR) and corresponding 95% confidence interval (95% CI) in order to quantify the risk associated with PDAC development. All factors with a P value of < 0.05 were considered statistically significant for all statistical analyses.

Statistical analysis. Univariate analysis was performed for each variable, using Pearson’s chi-square test for categorical variable and nonparametric Mann–Whitney U test for continuous variable. Unconditional univariate and multivariate logistic regression analyses were used to estimate odds ratio (OR) and corresponding 95% confidence interval (95% CI) in order to quantify the risk associated with PDAC development. All factors with a P value of < 0.05 and with potential clinical relevance were analyzed into a multivariate logistic regression analysis. Related variables were put through forward and backward stepwise regression of likelihood ratio in unconditional binary logistic regression analysis. To further investigate the influence in combined risk predictors, we performed a risk rating system to determine associations with PDAC occurrence. The referent for each independent variable was assigned a value of 0. Individual score was assigned to each participant’s record by summing the score of risk factors. Validity was assessed by the same method for each record. Statistical analyses were carried out using PASW 20.0 software (SPSS, Chicago, IL, USA). P values were based on two-sided tests and values of P < 0.05 were considered statistically significant for all statistical analyses.

Results
The basic information of studied objects. In our study, 88.2% PDAC patients had their duration of the disease less than 6 months, 64.1% had their location in pancreas head to neck, and 26.2% underwent radical surgery. As shown in Table 1, the average age of patients was 63.5 ± 11.3 years old, indicating that individuals in two groups were comparable (P > 0.05). Males accounted for 63.2% of the components of pancreatic malignant tumors. Men might be responsible for a positive risk factor. Compared with the control group, the percentage of PDAC patients was higher in smoking, family history of PDAC, diabetes, chronic pancreatitis, and cholecystectomy. A lower proportion of case group compared with the control group was seen in gastritis and gallbladder polyps. Blood indicators also demonstrated statistic differences of abnormal liver function and dyslipidemia. There were a higher TC/HDL-C ratio and a lower BMI in the case group, compared to the control group.

Table 1. Demographics and Clinical Characteristics in cancer patients and healthy subjects. Note: Mean ± SD for continuous variable and n (%) for categorical variable; BMI was calculated by dividing weight (kg) by height squared (m²); TC: Total cholesterol; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; AFU: alpha-L-fucosidase; FBG: fasting blood glucose; TC/HDL-C ratio: Total cholesterol divided by high-density lipoprotein-cholesterol; smoking and alcohol refer to ever smoking and ever alcohol drinking; Continuous variables are expressed as median values (interquartile range).

| Variable                             | Cases (n = 1274) | Controls (n = 3630) | Wald χ2/Z | P       |
|--------------------------------------|------------------|---------------------|-----------|---------|
| Male gender                          | 805 (63.2)       | 1835 (50.6)         | 60.6      | <0.001  |
| Age (years)                          | 63.5 ± 11.3      | 63.1 ± 6.6          | 0.169     |         |
| BMI (kg/m²)                          | 20.7 (18.7–22.7) | 24.4 (22.4–26.5)    | −32.1     | <0.001  |
| Smoking                              | 529 (41.5)       | 998 (27.5)          | 86.57     | <0.001  |
| Alcohol Drinking                     | 439 (34.5)       | 1246 (34.3)         | 0.007     | 0.931   |
| Family History of PDAC              | 35 (2.7)         | 48 (1.3)            | 11.51     | 0.001   |
| Diabetes                             | 203 (15.9)       | 297 (8.2)           | 61.9      | <0.001  |
| Gastritis                            | 26 (2.0)         | 88 (2.4)            | 0.61      | 0.435   |
| Pancreatitis                         | 53 (4.2)         | 6 (0.2)             | 126.6     | <0.001  |
| Cholelithiasis                       | 123 (9.7)        | 307 (8.5)           | 1.69      | 0.194   |
| Prior History of Cholecystectomy     | 64 (5.0)         | 26 (0.7)            | 97.12     | <0.001  |
| Gallbladder polyps                   | 28 (2.2)         | 360 (9.9)           | 77.13     | <0.001  |
| FBG (mmol/L)                         | 5.77 (5.11–6.83) | 5.11 (4.78–5.56)    | −17.7     | <0.001  |
| TC (mmol/L)                          | 4.27 (3.49–5.03) | 4.99 (4.28–6.55)    | −14.7     | <0.001  |
| Triglycerides (mmol/L)               | 1.30 (0.94–1.83) | 1.40 (0.96–2.08)    | −2.58     | 0.01    |
| HDL-C (mmol/L)                       | 1.11 (0.80–1.42) | 1.44 (1.19–1.71)    | −18.3     | <0.001  |
| LDL-C (mmol/L)                       | 2.35 (1.76–3.0)  | 2.94 (2.33–3.47)    | −12.8     | <0.001  |
| TC/HDL-C ratio                       | 3.59 (2.94–5.22) | 3.41 (2.88–4.06)    | −7.88     | <0.001  |
| Albumin/Globulin                     | 1.57 (1.35–1.79) | 1.75 (1.58–1.93)    | −18.2     | <0.001  |
| ALT (U/L)                            | 25 (13–86)       | 19 (14–27)          | 0.001     |         |
| AST (U/L)                            | 30 (19–82)       | 23 (19–27)          | 0.001     |         |
| ALP (U/L)                            | 122 (81–344)     | 78 (65–95)          | 0.001     |         |
| GGT (U/L)                            | 60 (21–366)      | 22 (15–35)          | 0.001     |         |
| AFU (U/L)                            | 17 (12–25)       | 20 (16–24)          | 0.001     |         |

Table 1. Demographics and Clinical Characteristics in cancer patients and healthy subjects. Note: Mean ± SD for continuous variable and n (%) for categorical variable; BMI was calculated by dividing weight (kg) by height squared (m²); TC: Total cholesterol; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; AFU: alpha-L-fucosidase; FBG: fasting blood glucose; smoking and alcohol refer to ever smoking and ever alcohol drinking. Continuous variables are expressed as median values (interquartile range).
Supplementary table compared the sensitivity and specificity of tumor markers between PDAC patients and healthy controls. Statistically based sensitivity and specificity of CA199 was 74.2% and 95.9%, and CA199&CA242 was 62.8% and 100% in PDAC risk in the study. These detailed and specific data was available as reference indicator for PDAC diagnosis.

Risk factors of case and control groups related to PDAC. In this analysis, major predictive indicators were significantly associated with increasing number of smoking, drinking, and TC/HDL-C ratio, family history of PDAC, chronic pancreatitis, cholelithiasis, prior history of cholecystectomy, and diabetes related to PDAC risk (P < 0.05, Table 2). Males that had a 1.68-fold risk in developing PDAC than females, implying that gender was associated with the risk of PDAC. There were statistically significant differences in the comparison of heavy smoking (>20 pack-year, OR = 2.4; 10~20 pack-year, OR = 2.2; <10 pack-year, OR = 1.0), heavy drinking (>1drink/day, OR = 2.2; 0~1drink/day, OR = 0.6), and new onset diabetes (<2 years, OR = 2.4; 2~5 years, OR = 1.7; >5 years, OR = 2.0) in the two groups, while the duration of CP (<8 years, OR = 34.9; >8 years, OR = 8.9) and cholecystectomy (<10 years, OR = 8.9; >10 years, OR = 6.0) did not play a primary role in statistic analyses.
Related significant risk factors of PDAC were put through forward and backward stepwise regression (Table 3). After removing mixed factors, seven risk factors including heavy smoking, heavy drinking, FH of PDAC, chronic pancreatitis, diabetes, cholecystectomy, and high TC/HDL-C ratio were independently involved with the development of PDAC (Table 3), and the OR(95%CI) of each independent predictor was 2.11 (1.76~2.53), 1.83 (1.46~2.29), 2.79 (1.70~4.58), 28.9 (11.9~69.9), 2.04 (1.63~2.56), 8.01 (4.83~13.3), and 5.75 (4.71~7.03), respectively.

**Risk score model in assessment on PDAC development.** To calculate a risk score for estimating the risk of PDAC occurrence, the value of each independent predictor was taken to integer as one. We assigned all referents a value of 0, the score for participants was calculated by summing their total number of risk factors (Table 4). A predictive factor risk score consisting of 1 point each for the seven risk factors predicted an increased risk of PDAC. The total possible score was 7 points, and actual scores ranged from 0 to 4. Compared with the low score (0), the OR values at high scores were sharply increased after jointing two or more risk factors. The higher risk scores, the extremely higher PDAC risk. The calculation of p for trend was proven to be statistically significant for the trend test.

**Discussion**

Without particularly strong risk factors or early detection tests, the PDAC patients suffered an extremely poor 5-year survival rate. Curative resection offers the only chance for long-term survival, which depends on early diagnosis of PDAC patients. Many researches on predisposing risk factors for the development of PDAC have been carried out for decades.

At univariate analysis, smoking is currently the only internationally recognized behavioral risk factor of PDAC, and 25% of PDAC result from smoking. Large amount of cigarette consumption contributed to 2.11 times increase in PDAC compared to non-smokers, and the risk estimates increased with the increasing amount of cigarettes. Smoking was associated with PDAC by 2~3 fold risks in many authoritative literatures, which may have a late-stage effect on pancreatic carcinogenesis even 15 years after smoking cessation. Although pancreas is not directly exposed to tobacco like lung, carcinogens in tobacco can be indirectly absorbed by lung through bloodstream into pancreas or by directly absorbed through digestive tract to the duodenal that refluxes to pancreas, causing detrimental effects. If the second mechanism exists, it can be explained to a certain extent why the majority of PDAC took place in the head of pancreas.

Alcohol consumption on the risk of PDAC remains controversial, and there was an increased risk of PDAC among male heavy alcohol drinkers in a pooled analysis. Alcohol is not only increase the reaction of pancreas

| Variables                      | OR (95%C.I.) | P value |
|--------------------------------|--------------|---------|
| Heavy smoking                  | 2.11 (1.76~2.53) | <0.001  |
| Heavy drinking                 | 1.83 (1.46~2.29) | <0.001  |
| Family History of PDAC         | 2.79 (1.70~4.58) | <0.001  |
| Chronic Pancreatitis           | 28.9 (11.9~69.9) | <0.001  |
| Diabetes                       | 2.04 (1.63~2.56) | <0.001  |
| Prior History of Cholecystectomy | 8.01 (4.83~13.3) | <0.001  |
| TC/HDL-C ratio >5              | 5.75 (4.71~7.03) | <0.001  |

**Table 3.** Multivariate logistic regression analysis of risk factors for PDAC. Note: Score of each variable is set to an integer of the logarithm of OR value; OR: standardized for age and gender. TC/HDL-C ratio: Total cholesterol/high-density lipoprotein-cholesterol ratio. Heavy smoking: Smoking >10 pack-year; Heavy drinking: Drinking >1 drink/day.

| Risk score* | Total Number | Controls (N = 3630) | Cases (N = 1034) | OR (95% CI) | p-value |
|-------------|--------------|---------------------|------------------|-------------|---------|
| 0           | 2729         | 2403                | 326              | 1.00 (referent) |         |
| 1           | 1300         | 930                 | 370              | 3.06 (2.57~3.65) | <0.001  |
| 2           | 497          | 263                 | 234              | 7.08 (5.63~8.91) | <0.001  |
| 3           | 107          | 28                  | 79               | 22.4 (14.2~35.4) | <0.001  |
| 4           | 31           | 6                   | 25               | 31.4 (12.7~77.5) | <0.001  |

**Table 4.** Scoring System of PDAC Risk Pattern in Each Score Category. Note: *Range for score was 0~7 actual points for 7 independent risk factors of PDAC, comprising heavy smoking (no, 0 points; yes, 1 point), alcohol consumption more than 1 drink/day (no, 0 points; yes, 1 point), alcohol consumption more than 1 drink/day, family history of PDAC (no, 0 points; yes, 1 point), chronic pancreatitis (no, 0 points; yes, 2 points), cholecystectomy (no, 0 points; yes, 1 point), diabetes (no, 0 points; yes, 1 point), TC/HDL-C ratio (0~5, 0 points; >5, 1 point). P for trend was 2-sided and based on the integer score for exposure risk of each level. OR: adjusted for age and sex. Missing data was 240 due to the lacking blood lipid profile in the case group.
to cholinergic and pancreozymin, but it also can increase the brittleness of pancreatic lysosomal enzymes and the activity of trypsin, making gradual destruction of pancreatic parenchymathe and occurrence of PDAC. The toxicity of acetaldehyde, upregulation of inflammatory and immunosuppressive reactions may also play a role in pancreas carcinogenesis.

Preexisting and new-onset DM both have been suggested a strong risk factor of PDAC in available studies. In this study, vast majority DM of case group was newly detected. Isaksson demonstrated that defects in insulin activity and glucose transport contribute to pancreatic cancer-associated insulin resistance on cellular level. Increasing evidences suggested that insulin resistance and subsequent hyperinsulinemia are common phenomena in diabetes, liver enzymes abnormalities and dyslipidemia, which have been verified associated with the promotion of PDAC development in vivo and vitro.

Nevertheless, a paucity of epidemiologic studies had examined the correlation of gallbladder disease, cholecystectomy, and dyslipidemia to the risk of PDAC development. Cholecystectomy had been proposed as potential risk factors for the development of cancers of ampulla and pancreas. An estimated 9–15% adults are afflicted with gallstones worldwide. Meanwhile, over 0.7 million cholecystectomies are performed in the United States every year. Cholecystectomy was reported to enhance pancreatic tumor formation in experimental animals. The presumed increased release of cholecystokinin was probably a culprit for the increased long-term risk of PDAC following cholecystectomy.

We found that the ratio of TC/HDL-C independently associated to the risk of PDAC. Chen's analysis suggests that a high intake of cholesterol could increase the risk of pancreatic cancer, especially in American society. We also discover at early time of the correlation between cholecystectomy and PDAC, which fit with Lin that found a 23% risk related to cholecystectomy.

A history of CP has been widely considered as a risk factor for PDAC. The duration of CP was suggested to be correlate with the degree of K-ras gene mutations. We had excluded patients who got cholecystolithiasis with CP to cancel the possibility that CP may confound the association between cholecystolithiasis and PDAC.

In this study, obesity does not show a clear association with the occurrence of PDAC. Besides, Chinese body type is usually slim, and the majority of PDAC patients before the Whipple operation are thin in the ward.

The highlights in the current study confirm those previously identified individual single factors into one overall model of an integer-based risk score system for evaluate setting on cumulative risk of PDAC. A highly statistically significant association of the risk score with all seven outcome measures was evaluated. Few institutions reported the selection algorithm of predictive risk score model to evaluate cancer risk. Previously proposed models, such as the APACHE or the POSSUM scoring system, are usually applicable in estimate of postoperative severity. However, they are difficult to be calculated and not suitable for preoperative probability of illness. In this population-based analysis, we have shown an effective demonstration of the joint effects of combined risk factors for PDAC, which provide a potential means to stratify individual risk at early stages. In a American hospital, a total of 1,616 subjects (808 PDAC patients and 808 healthy controls) were enrolled in a case-control study. It is found that smoking, family history, heavy alcohol consumption, diabetes mellitus, and history of pancreatitis were significant risk factors for pancreatic cancer, which is almost same to our study. Our study newly discovered two risk factors: prior history of cholecystectomy and TC/HDL-C ratio (+/-).

We found that combination of risk factors, in scoring system, had tighter relationships with the development of PDAC than that of a single risk factor. When two or more risk factors were considered into combination, strong association contributed to the development of PDAC. Those single risk factors related to PDAC were a priori expected. Our data indicate that it would be better to predict and prevent the PDAC development by using multifactoral analysis.

The combined risk factors may trigger a possibly significant synergistic effect, which may amplify PDAC risk. It was believed that the combined risk factors could stimulate the growth of PDAC cells via energy balance. The plausible effects of each factor are pleiotropic in nature with likely overlapping influence on noted pathways thought to be relevant to PDAC development, including lifestyle effects, insulin resistance, metabolic influence, and so on. For example, Ben and Dite advocated a synergistic effect of smoking and diabetes on PDAC risk. It was speculated that smoking combined with chronic pancreatitis was associated with a rather high risk of PDAC. In populations of chronic pancreatitis, the life-time risk of PDAC development is nearly 40% with high rates of smoking, while could below 20% for non-smokers. Patients could suffer an increased susceptibility to pancreatic DNA damage, chronic inflammation and becoming cancerous by smoking-induced oxidative stress. It has been reported that bile acids or certain metabolites in the bile may have a carcinogenic effect, and bile might contain chemical carcinogens that derived from tobacco, in case that someone is a current smoker.

Patients with diabetes and a history of CP had a 12-fold risk of PDAC than patients with either condition alone. It was suggested that alcoholic pancreatitis has a positive association in risk of PDAC. About 70% of pancreatitis cases are believed to be attributable to heavy alcohol consumption. In addition, if high-fat diet and smoking coexist, cholecystokinin and carbachol that associated with lipid metabolism will stimulate the accumulation of nicotine in pancreatic acini, and synergy of the two may even induce PDAC. In addition, a pooled analysis included a big number of PDAC cases concluded that heavy drinkers (>3 drinks/day) can result in an increased risk of PDAC. Genkinger and Michelle with their teams demonstrated a modest increase in risk of PDAC by heavy amounts of alcohol use but not by the type of alcohol. Tong and colleagues suggested that PDAC risk decreased as duration increased since diagnosis of pancreatitis. Our results are consistent with these previous reports.

This study provided sufficient evidence and showed clues for the risk prediction of PDAC by virtue of observation for various kinds of data between PDAC patients and health controls. Understanding pathways of combined risk for PDAC may provide perspectives into pancreatic carcinogenesis. If the above research is confirmed, a
better understanding of the etiology and an earlier detection of PDAC may help to reduce its incidence. The risk score for PDAC described here can serve as a model from which other studies may develop similar systems.

Of note, the major advantages are represented as follows: First, large number and high quality for the accuracy of the diagnostic confirmation of the patients group, restriction of microscopically confirmed cases generating the most valid estimates of risk. Second, adequate size and high representative of the control group. Third, large-scale collection and the use of multiple indicators of PDAC risk factors. Fourth, we minimized selection bias by including all cases and matched controls within the selected time period, adjusting them through appropriate and rigorous statistical methods. However, there are some limitations to the present study. First, due to a case-control study, it is unable to implement years of following-up direct exposure in developing PDAC. Second, a retrospective study is susceptible to have potential bias and selection bias. Third, because of the long age, some patients’ lipid profiles are lost, but this did not affect the overall outcome.

In summary, we have designed a risk score system to evaluate the risk of PDAC in high-risk populations. The results shown provided the best demonstration of the joint effects of combined risk factors for PDAC. This prediction risk score incorporating seven risk factors should be used for promotion and popularization. We believe that such a tool may be helpful in conjunction with early diagnosis of pancreatic cancer and allow for an accurate comparison of cancer predictors between institutions. It needs further validation using prospective evaluation in future clinical trials.

References
1. Wagner, M. et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91, 586–594 (2004).
2. Yadav, D. & Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252–1261 (2013).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J Clin 67, 7–30 (2017).
4. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 62, 10–29 (2012).
5. Nishimori, I. & Onishi, S. [Pancreatitis-associated gene mutations]. Nihon Rinsho 68, 2122–2127 (2004).
6. Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97, 1407–1427 (2005).
7. Lowenfels, A. B. & Maisonneuve, P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin North Am 36, 1–16 (2012).
8. Lowenfels, A. B. & Maisonneuve, P. Epidemiology and prevention of pancreatic cancer. Ipn J Clin Oncol 34, 238–244 (2004).
9. Ben, Q. et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 47, 248–254 (2011).
10. Fisher, W. E., Boros, L. G. & Schirmer, W. J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 63, 310–313 (1996).
11. Hennig, R., Ding, X. Z. & Adrian, T. E. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 19, 999–1011 (2004).
12. Genkinger, J. M. et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 18, 765–776 (2009).
13. Anderson, M. A. et al. Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol 107, 1730–1739 (2012).
14. Sand, J., Lankisch, P. G. & Nordback, I. Alcohol consumption in patients with acute or chronic pancreatitis. Pancreatology 7, 147–156 (2007).
15. Huang, H. et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 105, 1661–1669 (2010).
16. Isaksen, B. et al. Impaired insulin action in phosphoryldinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 26, 173–177 (2003).
17. Fischer, W. E., Boros, L. G. & Schirmer, W. J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 63, 310–313 (1996).
18. Mizuno, P. & Lowenfels, A. B. Chronic pancreatitis and pancreatic cancer. Dig Dis Sci 30, 32–37 (2002).
19. Shi, L., Kloppe, G., Maisonneuve, P., Lowenfels, A. B. & Luttges, J. Frequency of K-ras mutations in pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7, 17–23 (2005).
20. Heine, J. & Egan, K. M. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fum Cancer 8, 109–117 (2009).
21. Iiao, L. et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med 169, 784–790 (2009).
22. Wang, Y. et al. Association of CHRNA5-A3-B4 Variation with Esophageal Squamous Cell Carcinoma Risk and Smoking Behaviors in a Chinese Population. PLoS One 8 (2013).
23. Lynch, S. M. et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 170, 403–413 (2009).
24. Odegaard, A. O., Koh, W. P. & Yuan, J. M. Combined lifestyle factors and risk of incident colorectal cancer in a Chinese population. Cancer Prev Res 6, 360–367 (2013).
25. Wang, T. D. et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol 88, 737–743 (2001).
26. Mayerle, J. et al. Chronic pancreatitis–definition, etiology, investigation and treatment. Dtsch Arztebl Int 110, 387–393 (2013).
27. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, 35–20 (2003).
28. Hanley, A. J. et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54, 3140–3147 (2005).
29. Stolzenberg-Solomon, R. Z., Pietinen, P., Taylor, P. R., Virtamo, J. & Albanes, D. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 13, 417–426 (2002).
30. Hassan, M. M. et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102, 2696–2707 (2007).
31. Lin, G. et al. Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies. Cancer Causes Control 23, 59–67 (2012).
32. Chow, W. H. et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 79, 640–644 (1999).
33. Ura, H. et al. Combined effects of cholecystectomy and lithocholic acid on pancreatic carcinogenesis of N-nitosobis(2-hydroxypropyl)amine in Syrian golden hamsters. Cancer Res 46, 4782–4786 (1986).
35. Zhang, L. et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabolomic profiles. *Clin Biochem* **45**, 1064–1069 (2012).
36. Wu, Q. et al. Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: a case-control study in China. *Digestion* **86**, 294–301 (2012).
37. Shipeng S. R. X. Cholelithiasis. *Cholelithiasis* 1st Edition., 1–2 (2000).
38. Shaffer, E. A. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? *Curr Gastroenterol Rep* **7**, 132–140 (2005).
39. Chen H., Qin S., Wang M., Zhang T., Zhang S. Association between cholesterol intake and pancreatic cancer risk: evidence from a meta-analysis. *Sci Rep* **5** (2015).
40. Weber, S. M. et al. Laparoscopic left pancreatectomy: complication risk score correlates with morbidity and risk for pancreatic fistula. *Ann Surg Oncol* **16**, 2825–2833 (2009).
41. Hsu, C. C. et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. *J Gastrointest Surg* **16**, 753–761 (2012).
42. Chandra, A., Mangam, S. & Marzouk, D. A review of risk scoring systems utilised in patients undergoing gastrointestinal surgery. *J Gastrointest Surg* **13**, 1529–1538 (2009).
43. Dufour, M. C. & Adamson, M. D. The epidemiology of alcohol-induced pancreatitis. *J Gastrointest Surg* **13**, 2049–2055 (2009).
44. Dite, P. et al. [Pancreatic cancer–association with diabetes mellitus and smoking]. *Vnitr Lek* **57**, 159–162 (2011).
45. Talamini G. Duodenal acidity may increase the risk of pancreatic cancer in the course of chronic pancreatitis: an etiopathogenetic hypothesis: JOP. **6**(2), 122–7 2005 Mar 10.
46. Rebours, V. et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. *Am J Gastroenterol* **103**, 111–119 (2008).
47. Brodovicz, K. G. et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk, *Diabetes Obes Metab* **14**, 1123–1128 (2012).
48. Herreros-Villanueva, M., Hijona, E., Banales, J. M., Cosme, A. & Buja, L. Alcohol consumption on pancreatic diseases. *World J Gastroenterol* **19**, 638–647 (2013).
49. Wu, Q. et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. *J Gastrointest Surg* **16**, 753–761 (2012).
50. Shaffer, E. A. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? *Curr Gastroenterol Rep* **7**, 132–140 (2005).
51. Tong, G. X. et al. Association between pancreatitis and subsequent risk of pancreatic cancer: a systematic review of epidemiological studies. *Asian Pac J Cancer Prev* **15**, 5029–5034 (2014).

**Acknowledgements**

This study was supported by the Natural Science Foundation of China (No. 81572323) and Education Department Foundation of Zhejiang Province of China (No. Y201534694 and No. Y201534615).

**Author Contributions**

Tianshu Pang contributed as the first author, Guoping Ding and Zhengrong Wu concepted the study, Xiaofei Zhang and Yifei Yang managed the dataset and statistical analysis, Tianshu Pang and Guixing Jiang wrote the paper, Liping Cao provided academic inspection of the article.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-13182-w.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017